PATENT CLAIM ANALYSIS

Application Number: 15997965
Application Type: Utility
Filing Date: 2018-06
Publication Date: 2019-05
Patent Classification: ["514", "279000"]

Abstract:
The present invention relates to methods of treating metabolic syndrome, Type 2 diabetes mellitus, atherogenic dyslipidemia and/or obesity. The present invention a so relates to methods of restoring the incretin effect, to restoring physiologic control of glucagon levels, to restoring first-phase insulin secretion, and to restoring the physiologic glucose-dependent insulin secretion. The methods of the present invention comprise administration of a selective κ-receptor antagonist, such as guanidinylated naltrindole (GNTI), or pharmaceutically acceptable derivatives thereof to a subject in need thereof.

Claim (Index 5):
The method of  claim 3 , wherein the selective \u03ba-receptor antagonist is administered daily in an amount from about 8 ng to about 80 ng per kg of body weight daily.

Metadata:
- Claim Count in Document: 17.0
- Percentile: 94.0
- Lexical Diversity: 1.67273
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['13859940', '11876279', '14479828', '12906740', '12906735']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8085300101237
- 35 USC 102 Novelty (BERT): 0.5445867632695167
- Combined Prediction Score: 0.7821356854382816
- Mean Citation Score: 372.97859
- Max Citation Score: 390.9737
- Similarity Product: 382.1242033533097

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test